The phenotype of X-linked agammaglobulinemia (XLA) patients and the finding that BTK inhibition blocks downstream signaling underscores BTK’s central role in the BCR signaling pathway (Honigberg et al., 2010). Here, BTK is linked to Bruton-type agammaglobulinemia.